United Therapeutics Corporation
HealthcareNASDAQ:UTHR · NASDAQ Global Select
+$0.56 today
Vol 0.43M · Avg 0.54M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$3.2B of revenue converted into $1.3B of net income for the selected period. Gross margin is 86.6% and net margin is 40.6%, showing how much revenue survives after costs and taxes. EPS is $27.05, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.2B +10.6% | $2.9B +23.6% | $2.3B +20.2% | $1.9B +14.9% | $1.7B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $384.4M +24.1% | $309.7M +20.3% | $257.5M +75.5% | $146.7M +19.8% | $122.5M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $2.8B +9.0% | $2.6B +24.0% | $2.1B +15.7% | $1.8B +14.5% | $1.6B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 87.9% -1.3pp | 89.2% +0.3pp | 88.9% -3.5pp | 92.4% -0.3pp | 92.7% | 9.8% | 28.9% | 38.3% |
| Research & Development | $550.0M +14.3% | $481.0M +17.9% | $408.0M +26.4% | $322.9M -40.2% | $540.1M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $731.1M +14.5% | $638.6M +33.9% | $477.1M -2.0% | $487.0M +4.3% | $467.0M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $1.3B +7.6% | $1.2B +34.5% | $885.1M +9.3% | $809.9M -19.6% | $1.0B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $85.6M +18.1% | $72.5M +36.3% | $53.2M +3.7% | $51.3M +2.8% | $49.9M | $374.2M | $1.2B | $631.8M |
| EBITDA | $1.8B +9.9% | $1.7B +19.3% | $1.4B +33.3% | $1.0B +41.2% | $736.8M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 57.2% -0.3pp | 57.5% -2.1pp | 59.6% +5.9pp | 53.7% +10.0pp | 43.7% | 5.6% | 46.3% | 42.0% |
| Operating Income | $1.5B +10.2% | $1.4B +16.2% | $1.2B +20.9% | $979.7M +76.2% | $555.9M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 47.7% -0.2pp | 47.9% -3.1pp | 50.9% +0.3pp | 50.6% +17.6pp | 33.0% | 16.6% | 24.1% | 22.0% |
| Interest Income | $192.0M -3.6% | $199.1M +22.4% | $162.7M +260.0% | $45.2M +170.7% | $16.7M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $19.5M -54.5% | $42.9M -27.7% | $59.3M +83.0% | $32.4M +74.2% | $18.6M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $196.7M +21.4% | $162.0M +81.2% | $89.4M +407.2% | -$29.1M -176.6% | $38.0M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $1.7B +11.4% | $1.5B +20.8% | $1.3B +34.1% | $950.6M +60.1% | $593.9M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 53.9% +0.4pp | 53.5% -1.3pp | 54.7% +5.7pp | 49.1% +13.9pp | 35.2% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $379.2M +10.3% | $343.9M +18.8% | $289.5M +29.6% | $223.3M +89.1% | $118.1M | $1.3B | -$1.6B | $745.2M |
| Net Income | $1.3B +11.7% | $1.2B +21.4% | $984.8M +35.4% | $727.3M +52.9% | $475.8M | $4.9B | $4.8B | $4.7B |
| Net Margin | 41.9% +0.4pp | 41.5% -0.8pp | 42.3% +4.8pp | 37.6% +9.3pp | 28.2% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $30 +14.0% | $26 +25.7% | $21 +31.7% | $16 +50.8% | $11 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $28 +13.1% | $25 +24.4% | $20 +32.1% | $15 +49.1% | $10 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $44.3M -2.0% | $45.2M -3.4% | $46.8M +2.9% | $45.5M +1.3% | $44.9M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $47.9M -1.2% | $48.5M -2.4% | $49.7M +2.5% | $48.5M +2.5% | $47.3M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Biogen Inc.
NASDAQ:BIIB
$29.53B
Illumina, Inc.
NASDAQ:ILMN
$24.35B
Royalty Pharma plc
NASDAQ:RPRX
$23.60B
West Pharmaceutical Services, Inc.
NYSE:WST
$23.23B
Waters Corporation
NYSE:WAT
$23.17B
Quest Diagnostics Incorporated
NYSE:DGX
$22.48B
Incyte Corporation
NASDAQ:INCY
$21.68B
Zimmer Biomet Holdings, Inc.
NYSE:ZBH
$17.13B
Genmab A/S
NASDAQ:GMAB
$15.40B
Tenet Healthcare Corporation
NYSE:THC
$15.04B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does UTHR generate?
United Therapeutics Corporation (UTHR) reported $3.18B of revenue in fiscal 2025.
Is UTHR profitable?
United Therapeutics Corporation (UTHR) reported $1.33B of net income, with a net margin of 41.9%.
Explore More
Continue the stock analysis
Jump to another research area for this company.